Frequency of hospitalisation for respiratory infection · people with Duchenne muscular dystrophy and progressive respiratory decline
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life Assessed by: Pediatric Quality of Life Inventory, change from baseline (0 to 100; 0 = worst outcome, 100 = best outcome) · people with Duchenne muscular dystrophy and progressive respiratory decline
1 finding from 1 review
Serious adverse events · people with Duchenne muscular dystrophy and progressive respiratory decline
Idebenone showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Non‐serious adverse events · people with Duchenne muscular dystrophy and progressive respiratory decline
Idebenone showed no clear difference in non‐serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Change in disability score · children with SMA types II and III
1 finding from 1 review
Acquiring ability to walk · adults with SMA types II and III
1 finding from 1 review
Change in quality of life · adults with SMA types II and III
1 finding from 1 review
Change in pulmonary function · adults with SMA types II and III
1 finding from 1 review
Time from beginning of treatment until death or full‐time ventilation · adults with SMA types II and III
1 finding from 1 review
Adverse events related to treatment · adults with SMA types II and III
1 finding from 1 review
Change in disability score · children and adults with SMA types II and III
2 findings from 1 review
Muscle strength · children and adults with SMA types II and III
1 finding from 1 review
Acquiring the ability to stand or walk · children and adults with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in quality of life · children and adults with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Muscle strength · children with SMA types II and III
1 finding from 1 review
Change in pulmonary function · children and adults with SMA types II and III
1 finding from 1 review
Time from beginning of treatment until death or full‐time ventilation · children and adults with SMA types II and III
1 finding from 1 review
Adverse events related to treatment · children and adults with SMA types II and III
1 finding from 1 review
Change in disability score · children with SMA type II
Intrathecal injected nusinersen probably leads to higher change in disability score compared with sham procedure (moderate certainty).
1 finding from 1 review
Change in disability score (3 point‐change) · children with SMA type II
Intrathecal injected nusinersen showed no clear difference in change in disability score (3 point‐change) compared with sham procedure (moderate certainty).
1 finding from 1 review